HomeAI · summaries
Storia in 3 fonti
Biogen flips '26 guidance from expected decline to sales increase
With increased sales of its newer drugs compensating for declining revenues from its multiple sclerosis (MS) portfolio, Biogen is once again positioned for a “growth story,” CEO Chris Viehbacher sa | With increased sales of its newer drugs compensating for declining revenues from its multiple sclerosis portfolio, Biogen finally is positioned once again for a “growth story,” CEO Chris Viehbacher said Wednesday during the company’s second quarter earnings call. The company has flipped its 2026 revenue guidance from an expected mid-single digit decline in 2026 to a mid-single digit increase.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology push
Better-than-expected sales helped Biogen regain the support of investors, while AstraZeneca and GSK worked to convince Wall Street that they can hit ambitious revenue targets.
- ·
fiercepharma.com
Teva’s innovation engine offsets generics slump, leaving one analyst ‘shocked’ by Ajovy’s surge
As Teva proceeds down the more muted growth path that it telegraphed early this year, the generics and innovative medicines hybrid isn’t letting a little sales slump affect its…
